A federal appeals court has lifted a ban on federal funding for embryonic stem cell research.
Amy Ritter, PhD
Advertisement
Amy Ritter was Scientific Editor, BioPharm International.
Articles by Amy Ritter, PhD
The IMS institute has released its report on the use of medicines in the United States during 2010.
The US patent laws are undergoing a major revision, the first large revision since the Patent Act of 1952.
Nearly 900 therapies for the treatment, diagnosis or prevention of cancer are currently in development, according to a report released by PhRMA.
The National Institutes of Health?s (NIH) definition of embryonic stem (ES) cells poses new challenges for investigators who seek federal research funding.
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Signs Point to FDA Shelving Priority Voucher Pilot, Stalling Fast-Track Drug Reviews
2
Our Biggest Takeaways From AAPS PharmSci 360
3
PharmTech AI Pulse Check: Who's Accountable When a Vendor's AI Model Changes?
4
PharmTech’s Weekly Roundup—November 6, 2026: Impurities, Supply Resilience, and AI Accountability
5